- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108926
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers
The purpose of the study is to look at the levels of three HIV medications: tenofovir, emtricitabine, and efavirenz in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood. The study will specifically look at blood levels of these three drugs (taken as a 3-in-1 tablet) after taking them every day for 14 days.
This study is not randomised which means that all subjects will receive all study medications in the same order. You and the study doctor will know which study medications you are taking at all times during the study.
Study Overview
Detailed Description
The administration of combination antiretroviral therapy (cART) to HIV-infected patients has been associated with a dramatic reduction in AIDS-related morbidity and mortality [1-3].
The key to successful HIV drug treatment is adhering to the prescribed combination every day [2]. The approval of Atripla® (tenofovir/emtricitabine/efavirenz co-formulated in a single tablet) provides HIV care providers with a "one tablet once a day" therapy, making adherence much easier for patients.
However, in HIV therapy, successful adherence also means attention to intervals between doses or dietary restrictions. Ideally, to guarantee long-term virological response, HIV-infected patients should take their cART every day at the same time. However, cART is for life and doses can be forgotten or delayed.
Importantly, the 24-week 'Five-on-Two-off' (FOTO) study results were presented in November 2008; these showed that when HIV-infected patients stable (viral load < 50 copies/mL) on Atripla® were randomised to continue treatment daily or to stop taking it at weekends, no difference in maintenance of undetectable viral load was observed. Eighty percent in the control arm and 83% in the 'weekend off' arm had a viral load < 50 copies/mL [4]. This suggests that either the drugs' effects, or the drugs themselves, persist for a significant time following drug intake cessation. However, the persistence time and the inter-individual variability of this parameter for the components of Atripla® have not been clearly defined.
A drug's persistence in plasma or in cells depends on its half life. Long half-life antiretroviral agents may allow for missed or delayed doses, if concentrations are maintained at therapeutic levels until the next dose is taken. NRTI are pro-drugs and must be activated by different phosphorilation steps to be effective against HIV. Intracellular triphosphate (TP) metabolites have been shown to be characterized by long half lives. However, data on drug persistence are limited and whether drug doses can be omitted and dosing delayed is unknown.
Knowledge of the length of time the drug contained in the Atripla® formulation lasts would increase the confidence of doctors in this combination.
Importantly, triple regimen persistence should be investigated in order to provide information on the permissiveness (of forgotten or delayed doses) of the whole regimen rather than one single agent. Due to the simplicity of administering Atripla®, a study investigating the pharmacokinetic "forgiveness" of tenofovir and emtricitabine (in plasma and intracellularly) and plasma efavirenz would be readily performed in healthy volunteers and would provide information on how to advise HIV infected patients on delayed and missed doses.
Rationale for the pharmacogenomics analysis
Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multi antiretroviral drug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged.
From a public health perspective, as antiretroviral medications become increasingly available to racially and ethnically diverse populations worldwide, understanding the genetic structures of each population may allow us to anticipate the impact of adverse responses, even in groups that were not represented in drug registration trials.
The existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression underline the recent advances which occurred in the past few years.
However, it is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future. Additional studies are needed to assess the implications for long-term responses to antiretroviral agents.
For this reason we plan to collect a single blood sample from each participant in our intensive pharmacokinetic studies, such as this one, in order to be able to investigate the association between genetic polymorphisms in drug disposition genes (such as those encoding for cytochrome P450 isoenzymes or transmembrane transporters) and drug exposure. A candidate gene approach will be utilised to examine loci of interest. This procedure will provide potentially important information on genetic influences on plasma drug concentrations and give insight into how to improve the management of HIV-infected patients by individualising therapy. These studies will not be powered for genetic associations but will enable us to build a data base of genotype-phenotype. Prospective genetic studies would need to be planned based on these preliminary data.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW10 9TH
- St Stephen's Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria within 28 days prior to the baseline visit:
- The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements
- Male or non-pregnant, non-lactating females
- Between 18 to 65 years, inclusive
- Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 12 weeks after the study
- Willing to consent to their personal details being entered onto The Over volunteering Prevention Scheme (TOPS) database
- Willing to provide photographic identification at each visit.
- Registered with a GP in the UK
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
- Any significant acute or chronic medical illness
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
- Positive blood screen for hepatitis B surface antigen and/or C antibodies
- Positive blood screen for HIV-1 and/or 2 antibodies
- Current or recent (within 3 months) gastrointestinal disease
- Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study
- Exposure to any investigational drug or placebo within 3 months of first dose of study drug
- Use of any other drugs (unless approved by the Investigator), including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs.
- Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 12 weeks after the end of the treatment period
- Previous allergy to any of the constituents of the pharmaceuticals administered in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All Subjects
All Subjects will receive the same intervention
|
All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pharmacokinetics of plasma tenofovir, emtricitabine and efavirenz
Time Frame: 24 days
|
To assess the pharmacokinetics of plasma tenofovir and emtricitabine, and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, and plasma efavirenz over 10 days following drug intake cessation, in HIV negative healthy volunteers
|
24 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
inter subject variability
Time Frame: 24 days
|
To assess the inter subject variability in the concentrations of plasma tenofovir and emtricitabine, and their active intracellular anabolites, and plasma efavirenz following drug intake cessation
|
24 days
|
safety and tolerability of Atripla®
Time Frame: 24 days
|
To assess the safety and tolerability of Atripla® over 14 days of administration in HIV negative healthy volunteers
|
24 days
|
pharmacogenetic
Time Frame: 24 days
|
To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure
|
24 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Tenofovir
- Emtricitabine
- Efavirenz
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- SSAT 035
- 2009-018055-16 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Atripla®
-
Gilead SciencesCompletedHIV-1 InfectionFrance, United Kingdom, Spain, Belgium, Ireland
-
University of AlbertaUniversity of British Columbia; Gilead SciencesTerminated
-
Gilead SciencesCompletedHIV Infections | HIVCanada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
-
Gilead SciencesCompletedHIV-1 InfectionCanada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
-
Gilead SciencesCompletedHIV-1 InfectionSpain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
-
Gilead SciencesCompletedHIV Infections | HIVUnited States, Puerto Rico
-
SanofiCompleted
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
-
Merck Sharp & Dohme LLCCompleted